Patent details

EP4062913 Title: SOLID ORAL FORMULATION OF UTIDELONE

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Unitary Effect

Unitary Effect Requested:
Yes
Unitary Effect Request Filing Date:
06/06/2024
Unitary Effect Status:
Unitary Effect Request Filed
Request Unitary Effect Accepted:
20/06/2024
Unitary Effect Date:
08/05/2024
Unitary Effect Registration Date:
20/06/2024
Request Unitary Effect Rejected:
Unitary Effect Re-establishment of rights Filing Date:
Unitary Effect Re-establishment of rights EPO Decision :
Unitary Effect Re-establishment of rights EPO Decision Date:
Unitary Effect Request Withdrawal Date:
Unitary Effect request has been filed
UPP register:
EP4062913
SPC Number:
Creation Date:

Basic Information

Publication number:
EP4062913
WO Application Number:
CN2021116194
Type:
European Patent Granted for NL
Status:
Unitary Effect Registered
Publication Title:
Title When Made Available For Viewing:
Reason Lapsed:
Application number:
EP21863656.1
WO Publication Number:
WO2022048592
EPO Publication Language:
English
SPC Number:
First Applicant Residence Country:
China (CN)
Publications:

Dates

Filing date:
02/09/2021
Grant date:
08/05/2024
EP Publication Date:
28/09/2022
WO Publication Date:
10/03/2022
Claims Translations Received Date:
Claims Translation B1 Received Date:
Claims Translation B2 Received Date:
Claims Translation B3 Received Date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Published:
Due To Cession Date:
Registration date:
08/05/2024
EP B1 Publication Date:
08/05/2024
EP B2 Publication Date:
EP B3 Publication Date:
Description Translation B1 Received Date:
Description Translation B2 Received Date:
Description Translation B3 Received Date:
Expiration date:
01/09/2041
Lapsed By Expiration Date:
Revocation Date:
Invalidity Date:
Response To Novelty Search Report Received:
Patent Granting Request:
Lapsed date:

Applicant/holder

From:
08/05/2024
 
 

 

Name:
Beijing Biostar Pharmaceuticals Co., Ltd.
Address:
Suite 310, Building 3 No. 88 Kechuang 6th Street, Beijing 101111, China (CN)

From:
08/05/2024
 
 

 

Name:
CHENGDU BIOSTAR PHARMACEUTICALS, LTD.
Address:
No. 308 Kang Qiang 2nd Road Chengdu High Technology Zone Chengdu, Sichuan 611730, China (CN)

Inventor

1

Name:
TANG, Li
Address:
Beijing 101111, China (CN)

2

Name:
ZHANG, Chuan
Address:
Sichuan 611730, China (CN)

3

Name:
QIU, Rongguo
Address:
Beijing 101111, China (CN)

Priority

Priority Patent Number:
202010910072
Priority Date:
02/09/2020
Priority Country:
China (CN)

Classification

IPC or IDT classification:
A61K 31/427; A61K 9/20; A61K 9/22; A61K 9/50; A61K 47/30; A61P 35/00;

Publication

Bulletin

1

Bulletin Heading:
UP1
Journal edition number:
26/24
Publication date:
26/06/2024
Description:
European patents with registered Unitary Effect

2

Bulletin Heading:
EP2
Journal edition number:
19/24
Publication date:
08/05/2024
Description:
European patents granted for the Netherlands

European Patent Bulletin

1

Issue number:
202430
Publication date:
24/07/2024
Description:
Unitary Effect Request Acceptance

2

Issue number:
202429
Publication date:
17/07/2024
Description:
Unitary Effect Request Receipt

3

Issue number:
202419
Publication date:
08/05/2024
Description:
Grant (B1)

Annual Fee

Annual Fee(s) Due Date:
Annual Fee Number:
Last Annual Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Document Description Number of pages File Type